Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors

A technology based on alkyl and nitrile groups, applied in the field of new estratriene-triazole derivatives, can solve the problems of not being able to reach the level of T castration in men

Inactive Publication Date: 2009-08-12
SOLVAY PHARMA GMBH
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, Oefelein et al. reported that long-acting GnRH analogues failed to achieve castration levels of T in males in nearly 20% of cases [Oefelein MG & Cornum R(2000)] 23

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors
  • Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors
  • Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0272] definition

[0273] The following terms are used to describe the various components of the chemical compositions used in the present invention. The terms are defined as follows:

[0274] As used herein, the terms "comprises" and "including" are used herein in their open-ended, non-limiting sense.

[0275] The term "compound" is to be understood herein to encompass any and all isomers (such as enantiomers, stereoisomers, diastereomers, rotamers and tautomers), racemates or any mixture of isomers, prodrugs and any pharmaceutically acceptable salts of said compounds, unless the formula describing the compound clearly shows a particular stereochemistry.

[0276] When the plural form is used for compounds, salts, etc., it is also used to refer to a single compound, salt, etc.

[0277] The term "17β-hydroxysteroid dehydrogenase type I" or simply "17β-HSD1" is used for the enzyme EC 1.1.1.62, and reduces estrone (E1) to the biologically active estrogen, estradiol (E2) .

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and / or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17beta-hydroxysteroid dehydrogenase (17beta-HSD) such as 17beta-HSD type 1, type 2 or type 3 enzyme.

Description

technical field [0001] The present invention relates to novel estriferases representing inhibitory compounds of 17β-hydroxysteroid dehydrogenase, preferably type 1 (17β-HSD1), type 2 (17β-HSD2) or type 3 (17β-HSD3) 17β-hydroxysteroid dehydrogenase En-triazole derivatives, salts of these compounds, pharmaceutical preparations containing these compounds, and methods for preparing these compounds. Furthermore, the invention relates to the therapeutic use of said estratriene-triazole derivatives, in particular their use in the treatment or prevention of steroid hormone-dependent diseases or disorders, for example where inhibition of 17β-hydroxysteroid dehydrogenase, in particular type I Use of 17[beta]-HSD enzymes and / or steroid hormone-dependent diseases or disorders requiring regulation of endogenous 17[beta]-estradiol and / or testosterone concentrations. Background technique [0002] The publications and other materials used herein to illustrate the background of the inventio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07J43/00A61K31/58A61P35/00A61P13/00A61P5/32
Inventor J·梅辛格U·舍恩B·胡森H-H·托勒P·科斯基米耶斯L·卡利奥H－H·托勒
Owner SOLVAY PHARMA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com